Fri, Aug 1, 2014, 11:56 PM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

Exelixis, Inc. Message Board

  • breezerwave breezerwave Feb 11, 2013 9:33 PM Flag

    Phase 2 study actively recruiting - Cabozantinib for Advanced Urothelial Cancer

    "Background:

    - Cabozantinib is a drug that slows the growth of blood vessels that feed tumors. It has not been approved for cancer treatment. However, studies have shown that prostate and ovarian tumors respond to it. Researchers want see if cabozantinib can be a safe and effective treatment for urothelial cancer."

    See clinical trials in progress.

    Sentiment: Strong Buy

 
EXEL
4.19+0.16(+3.97%)Aug 1 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.